



Q1 2022 EARNINGS CALL



Forward looking statement



This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the conditions for the drawdown of the second and third tranches of the Kreos Capital loan and how the loan agreement broadens the Company’s financing options and provides it with access, on a non-dilutive basis, to significant additional capital, the Company’s pipeline, the expected benefits from recent executive appointments, the expected timing and recruitment for trials, the Interim Analysis, its expected timing, the release of its results and their potential implications, future commercialization of the Company’s products, the potential benefits of D-PLEX100 and OncoPLEX, market opportunity for DPLEX₁₀₀, the US addressable market for DPLEX₁₀₀, its ongoing pre-commercialization preparations and pre-launch activities, the Company’s potential partners, additional publications and presentations at important scientific conferences and the sufficiency of the Company’s cash to fund future operations into the second quarter of 2023. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 28, 2022. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.



References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Opening Remarks



Presentations and conferences

SAGES 2022
DENVER, CO

SIS Surgical Infection Society

CLINAM
European Foundation for Clinical Nanomedicine

D-PLEX₁₀₀, a novel doxycycline formulation that provides high, local concentrations of antibiotic activity for approximately four weeks to reduce Surgical Site Infections

- SAGES 2022 annual meeting the next big thing

Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation

-SIS Annual meeting April 2022

From Bench to Bedside: D-PLEX limits AMR occurrence in randomized double-blind phase 2 trial in colorectal surgery patients


- CLINAM 2022 virtual meeting

All publications can be found on our website at polypid.com/publications/

SHIELD I enrolled approximately 900 patients to the study

Enrolment continues at a rate of 200 – 250 patients per quarter


SHIELD I patient enrolment since trial initiation



- Interim analysis ongoing based on the first 750 patients
- Results from DMC expected imminently
- An early stop to the trial can occur if the efficacy of D-PLEX₁₀₀ is better than expected
- Opportunity to define the targeted patient enrollment range for the SHIELD I study

Total US addressable market (TAM) for D-PLEX₁₀₀ is over 12.2M procedures

Number of surgeries in DPLEX target indications (M)



Main drivers of surgery volumes

Abdominal surgeries:

- Herniorrhaphies – 2.1M / year
- Cholecystectomies – 616K / year
- Colorectal resection – 544K / year

Gynecology & Urology surgeries

- Hysterectomies – 660K / year
- Oophorectomies – 1.1M / year

Orthopedic surgeries:

- Joint replacement – 1.8M / year
- Long bone fraction – 2M / year
- Spine procedures – 1M / year

Strengthening our management



DALIT HAZAN

Executive Vice President heading R&D, and Clinical & Regulatory Affairs

- Over 20 years of experience in the pharmaceutical industry
- Vast experience in leading the regulatory strategy and submissions of different pharmaceutical dosage forms in the FDA, EMA and other markets.
- Previously at Teva Pharmaceuticals
- Joined PolyPid in 2016



EVGENY VALDMAN

Executive Vice President, Technical Operations

- 25 years of experience in managing all aspects of drug manufacturing including sterile production
- Responsible for manufacturing, engineering, supply chain logistics, and quality affairs
- Previously at Teva Pharmaceuticals

Balance Sheet

U.S. dollars in thousands

	March 31, 2022	December 31, 2021
	<i>Unaudited</i>	<i>Audited</i>
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 11,434	\$ 9,819
Restricted cash	393	397
Short-term deposits	12,187	22,384
Prepaid expenses and other current assets	1,478	2,211
Total current assets	25,492	34,811
LONG-TERM ASSETS:		
Property and equipment, net	9,338	8,761
Other long-term assets	651	663
Total long-term assets	9,989	9,424
Total assets	\$ 35,481	\$ 44,235

	March 31, 2022	December 31, 2021
	<i>Unaudited</i>	<i>Audited</i>
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Trade payables	\$ 3,214	\$ 4,136
Accrued expenses and other current liabilities	3,227	3,940
Total current liabilities:	6,441	8,076
LONG-TERM LIABILITIES:		
Other liabilities	195	199
Total long-term liabilities:	195	199
COMMITMENTS AND CONTINGENT LIABILITIES		
SHAREHOLDERS' EQUITY:		
Ordinary shares with no par value -		
Authorized: 47,800,000 shares at March 31, 2022 (unaudited) and December 31, 2021; Issued and outstanding: 19,470,757 and 18,756,570 shares at March 31, 2022 (unaudited) and December 31, 2021, respectively	-	-
Additional paid-in capital	215,606	210,847
Accumulated deficit	(186,761)	(174,887)
Total shareholders' equity	28,845	35,960
Total liabilities and shareholders' equity	\$ 35,481	\$ 44,235

Statement of Operations

U.S. dollars in thousands (except share and per share data)

	<i>Three Months Ended March 31, 2022 Unaudited</i>	<i>Three Months Ended March 31, 2021 Unaudited</i>
Operating expenses:		
Research and development, net	\$ 8,697	\$ 6,018
Marketing and business development	775	652
General and administrative	2,480	2,127
Operating loss	11,952	8,797
Financial income, net	78	110
Loss	\$ 11,874	\$ 8,687
Basic and diluted loss per Ordinary share	\$0.63	\$0.47
Weighted average number of Ordinary shares used in computing basic and diluted loss per share	18,936,457	18,623,154

Q & A

